AiverseWorld logo

AiverseWorld

Compare

Compare AI tools with a clear side-by-side workflow

Start with two products, then move into pricing, capability, platform fit, and practical tradeoffs.

Selected comparison

AbSci AI vs Insilico Medicine

This comparison was retrieved by database IDs selected from the catalog.

AbSci AI favicon

AbSci AI

AbSci

Insilico Medicine favicon

Insilico Medicine

Insilico Medicine

Overview
Rating
—
—
Category
Developer Tools
Developer Tools
Subcategory
Generative AI Drug Discovery
AI Drug Discovery
Company
AbSci
Insilico Medicine
Status
Active
Active
Launch year
2023
2014
Tags
drug-discoveryaibiotechantibodygenerative-aipharma
drug-discoveryaipharmaceuticalgenerative-chemistrybiotechclinical
Pricing
Starting price
FreeBest value
Free
Pricing model
Enterprise
Enterprise
Free plan
No
No
Free trial
✕
✕
Pricing notes

Pharmaceutical partnership model. No public pricing. Publicly traded company (ABSI). Research collaborations.

Enterprise and institutional licensing for pharmaceutical partners. No public access. Public company listed on NASDAQ.

Capabilities
Best for
Antibody drug candidate generationProtein therapeutic designAI drug discovery for pharma partnershipsIn silico molecular screeningGenerative biology platform
AI-first novel drug candidate designTarget identification for specific diseasesDrug repurposingADMET property optimisationPreclinical research acceleration
Target audience
Pharmaceutical companiesBiotechnology research teamsAcademic drug discovery researchersSynthetic biology researchersBiotech investors
Pharmaceutical companiesBiotech companiesAcademic research institutionsDrug discovery CROsOncology and CNS research teams
AI type
Deep Learning Model
ML Platform
Modalities
Data
Data
Technical
Model provider
AbSci
Insilico
Model names
—
Chemistry42PandaOmics
API available
✕
✓
Open source
✕
✕
Deployment
SaaSResearch partnership
SaaSEnterprise partnership
Platforms
WebAPI
WebAPI
Integrations
Pharmaceutical research systemsAPI
Major pharmaceutical ERP and research systemsAPI
Team collaboration
✕
✕
Trust & security
Security

Research data handling agreements. GDPR compliant. Enterprise pharmaceutical partnership data handling agreements.

Enterprise research data handling agreements. GDPR compliant. Research use data protected under partnership terms.

Privacy notes

Biological research data and drug candidate designs handled under pharmaceutical partnership data handling agreements and applicable research ethics frameworks.

Drug discovery research data processed under enterprise partnership data handling agreements. Review applicable regulatory requirements for clinical programme data.

Verdict
Pros
  • Published zero-shot antibody design research in peer-reviewed journals validates the generative AI approach
  • Publicly traded company provides financial transparency and stability versus private biotech competitors
  • Generative design approach creates novel molecules rather than optimising existing ones — different innovation mode
  • Pharmaceutical partnership model provides revenue without requiring AbSci to advance drugs independently through clinical trials
  • INS018_055 in Phase 2 clinical trials is the most advanced AI-designed drug in human trials
  • Chemistry42 generative AI designs novel molecules rather than only screening existing libraries
  • First company to advance a fully AI-designed drug candidate to clinical trials
  • NASDAQ listing (ILAB) provides financial transparency for pharma partnership assessment
Cons
  • Very early commercial stage — generative AI drug discovery has not yet produced approved drugs
  • Pharmaceutical partnership revenue is lumpy and dependent on partner decisions and clinical outcomes
  • Competing with well-funded competitors including Recursion, Insilico Medicine, and Isomorphic Labs
  • Drug discovery is inherently long-cycle — AI acceleration is still measured in years, not weeks
  • Clinical success probability remains uncertain — most drug candidates fail in clinical trials
  • Enterprise partnership model means capabilities are not broadly accessible as a self-serve platform

Trending comparisons

120 curated matchups

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement